Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), has announced significant progress in its Phase 3 program for HLP003, a potential treatment for major depressive disorder (MDD). The company recently reported that enrollment has been completed in APPROACH, the first pivotal Phase 3 study, with topline data expected in the fourth quarter of 2026. This milestone brings Helus Pharma closer to potentially addressing the large unmet need for patients with MDD who do not adequately respond to existing therapies.
The APPROACH study is part of the PARADIGM program, which includes EMBRACE, a second pivotal study that is currently enrolling participants. Additionally, the EXTEND study, which evaluates long-term safety and efficacy, continues to roll over participants from the earlier trials. The advancement of these studies underscores Helus Pharma's commitment to rigorously evaluating HLP003, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of MDD. This designation highlights the potential of HLP003 to offer a significant improvement over available treatments.
In addition to the progress in MDD, Helus Pharma is advancing its pipeline. HLP004, a novel serotonergic agonist for generalized anxiety disorder (GAD), demonstrated statistically significant and clinically meaningful improvement from baseline in Phase 2 results. The company expects to complete the design of the next study for HLP004 by the end of the third quarter of 2026, signaling continued momentum in its development efforts. Furthermore, Helus Pharma is advancing HLP005 toward candidate selection, with a viable development candidate anticipated in the second half of 2027.
The company's financial position appears solid to support these initiatives. As of June 30, 2026, Helus Pharma reported cash of $166.4 million and a quarterly net loss of $47.8 million, compared with $24.6 million in the same period last year. Cash-based operating expenses increased to $37.5 million from $23.9 million, driven by the ongoing Phase 3 trials. These investments reflect the company's focus on advancing its clinical programs and bringing innovative treatments to patients.
The implications of these developments are significant for the mental health treatment landscape. Major depressive disorder affects millions worldwide, and many patients do not achieve remission with current antidepressants. HLP003, as an NSA, aims to activate serotonin pathways believed to promote neuroplasticity, potentially offering durable improvements in mental health. If successful, HLP003 could provide a new option for patients who have not responded to existing therapies, addressing a critical unmet need.
Similarly, HLP004 could offer a new approach to treating generalized anxiety disorder, a condition that also has substantial unmet needs. The positive Phase 2 results are encouraging, and the advancement to the next stage of development is a positive signal for the company's pipeline.
Investors and stakeholders are watching these developments closely, as the outcomes of the Phase 3 trials will be pivotal for Helus Pharma's future. The company's commitment to advancing its pipeline, combined with its financial resources, positions it to potentially bring novel treatments to market. For more information, visit the company's newsroom at https://ibn.fm/HELP.
